Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study

Infection
Basima A AlmomaniMiral A Al Momani

Abstract

To assess incidence rate, risk factors and susceptibility patterns associated with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae in community-acquired urinary tract infections (CA-UTIs). A prospective, case-control study was conducted at a tertiary teaching hospital from Jan 2015 to Dec 2016. The results of microbiology cultures were initially screened to include only patients with positive E. coli or K. pneumoniae urine cultures. Afterwards, clinical symptoms were assessed to confirm the UTI. To investigate the risk factors, patients with a positive urine culture for ESBL-producing isolates were assigned as cases, while patients with non-ESBL were assigned as controls. Out of 591 patients included in this study, 57.5% (n = 340) were included in the control group and 42.5% (n = 251) were in the case group. The incidence rate of ESBL-producing isolates was 3.465 cases per 1000-patient hospital admissions. Male gender (OR = 1.856, 95% CI = 1.192-2.889, p = 0.006), pediatrics (OR = 1.676, 95% CI = 1.117-2.517, p = 0.013), patients with comorbidity (OR = 1.542, 95% CI = 1.029-2.312, p = 0.036) and UTI in the previous 12 months (OR = 1.705, 95% CI = 1.106-2.628, p = 0.016) were independe...Continue Reading

References

Oct 14, 2005·International Journal of Antimicrobial Agents·Amal G Al-BakriAl-Motassem Yousef
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Jul 23, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronen Ben-AmiYehuda Carmeli
Aug 20, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O K AzapS S Senger
Feb 13, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Rezan TopalogluDeniz Gur
Jul 9, 2010·Current Opinion in Infectious Diseases·Jesús OteoJosé Campos
Jan 21, 2011·The Pediatric Infectious Disease Journal·Athanasios TratselasEmmanuel J Roilides
Jan 29, 2011·Scandinavian Journal of Infectious Diseases·Nazan DalgicSuleyman Pelit
Aug 18, 2012·International Journal of Clinical Practice·L S Briongos-FigueroJ L Pérez-Castrillón
Jul 10, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Nai-Chia FanCheng-Hsun Chiu
Sep 26, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Pei-Chun ChenLi-Min Huang
Apr 29, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Wail A HayajnehRobert E Badal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.